Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain

Arch Intern Med. 2002 Dec;162(22):2639-40; author reply 2640-2. doi: 10.1001/archinte.162.22.2639-a.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Letter

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Case-Control Studies
  • Cyclooxygenase Inhibitors / administration & dosage
  • Cyclooxygenase Inhibitors / adverse effects*
  • Female
  • Humans
  • Lactones / administration & dosage
  • Lactones / adverse effects*
  • Male
  • Myocardial Infarction / epidemiology*
  • Myocardial Infarction / etiology*
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Risk Factors
  • Sensitivity and Specificity
  • Sulfones

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib